OBX (Obsidian Therapeutics) Marketable Securities: $40.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics Marketable Securities?

Obsidian Therapeutics OBX -1.79% 8 Marketable Securities is $40.08 Mil as of Dec. 2025. GuruFocus rates OBX with a GF Score™ of 8/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Obsidian Therapeutics's Marketable Securities for the quarter that ended in Dec. 2025 was $40.08 Mil.

Obsidian Therapeutics's annual Marketable Securities increased from . 20 ($0.00 Mil) to Dec. 2024 ($118.51 Mil) but then declined from Dec. 2024 ($118.51 Mil) to Dec. 2025 ($40.08 Mil).

Obsidian Therapeutics  (NAS:OBX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Obsidian Therapeutics Marketable Securities Related Terms

Obsidian Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics Marketable Securities Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
Marketable Securities
118.51 40.08

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
Marketable Securities 118.51 40.08
OBX
8GF Score
Obsidian Therapeutics Inc OBX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $40.08 Mil mean?
Obsidian Therapeutics (OBX) has a Marketable Securities of $40.08 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' Marketable Securities too high?
Obsidian Therapeutics' current Marketable Securities is $40.08 Mil. Overall, Obsidian Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' Marketable Securities compare to ?
Obsidian Therapeutics' Marketable Securities of $40.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Obsidian Therapeutics and its competitors. Obsidian Therapeutics's current Marketable Securities is $40.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current Marketable Securities of $40.08 Mil. The current Marketable Securities is $40.08 Mil. Obsidian Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current Marketable Securities is $40.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price